Table 3.
Presumed germline mutations based on the CGPT results.
| No. | ID (in this Cohort) |
CGPT | Diagnosis | Age | Gender | Gene Aberration | Blood Sample Diagnosis | Therapeutic Drug Accesibility |
|---|---|---|---|---|---|---|---|---|
| 1 | 92_GBM | F-One | GBM, IDH-wt | 91 | M | BRCA2 R2318* | no | no |
| 2 | 101_GBM | F-One | GBM, IDH-wt | 59 | F | MSH6 C694fs*4, MSH6 I795fs*15 | no | Yes (Pembrolizumab) * |
| 3 | 104_DA_NEC | NOP | Diffuse Astrocytoma, IDH-wt, NEC | 51 | F | NF1 Q2434* | Yes | no |
| 4 | 115_AST | F-One | Astrocytoma, IDH-mt | 51 | M | MSH6 Y524fs*46 | no | no |
| 5 | 119_OLG | F-One | Oligodendroglioma, IDH-mt | 52 | F | BRCA2 I682fs*48 | no | Yes (Pembrolizumab/Olaparib) * |
NEC: Not Elsewhere Classified, NOP: OncoGuideTM, NCC OncoPanel System, NOP can confirm germline mutations by comparing peripheral blood DNA and tumor tissue DNA. (*): enrollment in a clinical trial is pending, considering other therapeutic options.